CDA Deficiency as a Possible Culprit for Life-Threatening Toxicities After Cytarabine Plus 6-Mercaptopurine Therapy: Pharmacogenetic Investigations
- 1 March 2012
- journal article
- case report
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 13 (4) , 393-397
Abstract
We describe here the case of a 7-year old girl with lymphoma who developed life-threatening toxicities upon cytarabine plus mercaptopurine. Surprisingly, initial investigations on canonical thiopurine methyltransferase genetic polymorphism proved to be negative. We focused next on deregulations affecting the CDA gene implicated in the liver disposition of cytarabine. This patient was homozygous for both the 79A>C and the -31delC polymorphisms on the CDA gene and promoter, two genotypes with reported opposite effects on CDA phenotype. To determine the CDA status of this patient, additional functional testing was performed and eventually demonstrated that this patient was a poor metabolizer. This case demonstrates that besides affecting thiopurine methyltransferase, dysregulations with CDA should be screened to anticipate toxicities with the cytarabine plus mercaptopurine combination.Keywords
This publication has 18 references indexed in Scilit:
- Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression riskPLoS Currents, 2011
- Variability in Transport and Biotransformation of Cytarabine is Associated with its Toxicity in Peripheral Blood Mononuclear CellsPharmacogenomics, 2011
- A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot SyndromeClinical Cancer Research, 2011
- Identification of Predictive Markers of Cytarabine Response in AML by Integrative Analysis of Gene-Expression Profiles with Multiple PhenotypesPharmacogenomics, 2011
- Integrating pharmacogenetics into gemcitabine dosing—time for a change?Nature Reviews Clinical Oncology, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine DosingClinical Pharmacology & Therapeutics, 2011
- Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical applicationThe Journal of Pathology, 2010
- High-Resolution Melting Analysis of Sequence Variations in the Cytidine Deaminase Gene (CDA) in Patients With Cancer Treated With GemcitabineTherapeutic Drug Monitoring, 2010
- Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based ChemotherapiesJournal of Clinical Oncology, 2010
- Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer PatientsClinical Cancer Research, 2008